Ilan Sobel - Bioharvest Sciences Chief Officer
| CNVCF Stock | USD 6.15 0.03 0.49% |
Insider
Ilan Sobel is Chief Officer of Bioharvest Sciences
| Phone | 604 622 1186 |
| Web | https://www.bioharvest.com |
Bioharvest Sciences Management Efficiency
The company has return on total asset (ROA) of (0.5264) % which means that it has lost $0.5264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (63.6438) %, meaning that it generated substantial loss on money invested by shareholders. Bioharvest Sciences' management efficiency ratios could be used to measure how well Bioharvest Sciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Advocate Ohayon | INC Research Holdings | 35 | |
| Muthusamy RPh | ANI Pharmaceuticals | 56 | |
| CCFP DipSportMed | Evolus Inc | 60 | |
| Mark Baldyga | Biofrontera | N/A | |
| Jeff Holm | Biofrontera | N/A | |
| BComm BCom | Akanda Corp | 68 | |
| Sibyl Swift | cbdMD Inc | 43 | |
| Matthew Coapman | cbdMD Inc | 48 | |
| Raymond Coffman | cbdMD Inc | 62 | |
| Kevin MacDermott | cbdMD Inc | 62 | |
| Marlo Manning | Collegium Pharmaceutical | N/A | |
| Erica CPA | Biofrontera | 39 | |
| Tejinder Virk | Akanda Corp | 42 | |
| BCom BAcc | Akanda Corp | 44 | |
| Eugene III | Biofrontera | 39 | |
| Rami Levy | INC Research Holdings | 59 | |
| Sandra Beaver | Evolus Inc | 46 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| OriMoni Mimon | INC Research Holdings | 36 | |
| Alex Dasalla | Collegium Pharmaceutical | N/A | |
| Richard MD | Collegium Pharmaceutical | 64 | |
Management Performance
| Return On Equity | -63.64 | |||
| Return On Asset | -0.53 |
Bioharvest Sciences Leadership Team
Elected by the shareholders, the Bioharvest Sciences' board of directors comprises two types of representatives: Bioharvest Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bioharvest. The board's role is to monitor Bioharvest Sciences' management team and ensure that shareholders' interests are well served. Bioharvest Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bioharvest Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Zaki Rakib, CoFounder Chairman | ||
| BCom BComm, Chief Officer | ||
| Brian Cornblatt, Chief Officer | ||
| David Ryan, S Relations | ||
| Yochi Hagay, CTO CoFounder | ||
| Ilan Sobel, Chief Officer |
Bioharvest Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Bioharvest Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -63.64 | |||
| Return On Asset | -0.53 | |||
| Profit Margin | (2.69) % | |||
| Operating Margin | (2.45) % | |||
| Current Valuation | 106.97 M | |||
| Shares Outstanding | 460.72 M | |||
| Shares Owned By Insiders | 35.15 % | |||
| Price To Book | 91.96 X | |||
| Price To Sales | 28.13 X | |||
| Revenue | 2.1 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Bioharvest OTC Stock
Bioharvest Sciences financial ratios help investors to determine whether Bioharvest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bioharvest with respect to the benefits of owning Bioharvest Sciences security.